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Oligopeptide repeats appear in many proteins that undergo
conformational conversions to form amyloid, including the
mammalian prion protein PrP and the yeast prion protein
Sup35. Whereas the repeats in PrP have been studied more
exhaustively, interpretation of these studies is confounded by
the fact that many details of the PrP prion conformational con-
version are notwell understood.On the other hand, there is now
a relatively good understanding of the factors that guide the
conformational conversion of the Sup35 prion protein. To pro-
vide a general model for studying the role of oligopeptide
repeats in prion conformational conversion and amyloid forma-
tion, we have substituted various numbers of the PrP octare-
peats for the endogenous Sup35 repeats. The resulting chimeric
proteins can adopt the [PSI] prion state in yeast, and the sta-
bility of the prion state depends on the number of repeats. In
vitro, these chimeric proteins form amyloid fibers, with more
repeats leading to shorter lag phases and faster assembly rates.
Both pH and the presence of metal ions modulate assembly
kinetics of the chimeric proteins, and the extent of modulation
is highly sensitive to the number of PrP repeats. Thiswork offers
new insight into the properties of thePrPoctarepeats in amyloid
assembly and prion formation. It also reveals new features of the
yeast prion protein, and provides a level of control over yeast
prion assembly that will be useful for future structural studies
and for creating amyloid-based biomaterials.
Prions were originally recognized as the causative agent of
several mammalian neurodegenerative disorders, including
scrapie in sheep, bovine spongiform encephalopathy (mad cow
disease) in cattle, and Creutzfeldt-Jakob disease (CJD) in
humans (1). According to the prion hypothesis, these maladies
are due to a conformational conversion of the normal cellular
prion protein (PrPC)4 into an abnormal pathological isoform
(PrPSc), a portion of which becomes highly resistant to protein-
ase-K digestion. Once prion formation is initiated (i.e. sponta-
neous conversion of cellular PrPC to PrPSc to generate infectiv-
ity), the PrPSc conformers can self-replicate by templating the
conformational conversion of other PrPCmolecules (1). Several
prion-like proteins identified in yeast can also perpetuate their
conformational states through a protein-based templating
mechanism. Instead of causing fatal diseases, however, the
yeast prions are sometimes beneficial, and can act as protein-
only elements of inheritance (2). For instance, the yeast prion
phenotype [PSI] is the result of the self-replicating conforma-
tional conversion of the protein Sup35, a translation termina-
tion factor. In its prion conformation, Sup35 is sequestered
from its normal function, resulting in increased read-through
of nonsense codons. This read-through can ultimately confer a
wide spectrum of heritable new phenotypes (3–5). In vitro the
Sup35 prions can form amyloid fibers in a template-based reac-
tion that is thought to parallel in vivo prion conformational
conversion and is reminiscent of the fiber formation of a wide
range of amyloidogenic proteins (2).
The mammalian PrP and yeast Sup35 share several similar
structural characteristics, including a well-folded C-terminal
core and a natively unfoldedN terminus. TheN termini of both
proteins contain oligopeptide repeats that influence their con-
formational conversion to the prion state (6–10). The N termi-
nus of wild-type human PrPC contains four perfect copies of a
highly conserved octarepeat sequence (11), PHGGGWGQ, and
one imperfect copy, PQGGGTWGQ. Expansion of the octare-
peat region, ranging from one to nine extra copies, has been
found in several types of familial CJD and is associated with an
earlier onset of pathology (12, 13). When transgenic mice that
express repeat-free PrP are infected by scrapie extracts or by
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PrP aggregates, they showa slower progression of disease (9, 14)
and exhibit different histopathological characteristics than
mice with the wild-type protein (15). In vitro, expansion of the
octarepeat region increases the spontaneous conversion rate of
PrPC to a protease-resistant conformation (16). Likewise, when
the octarepeat region is fused to a GST (glutathione S-transfer-
ase) protein, it accelerates protein self-association and allows
selective binding of PrPSc from brain extracts (17). Sup35 has
five imperfect copies of PQGGYQQYN. Reducing the number
of repeats lowers the frequency of spontaneous prion induction
(7, 18). Furthermore, the prion state associatedwith this variant
is unstable and frequently spontaneously converts back to the
non-prion state, [psi] (7). Sup35 with an expanded number of
repeats, however, induces a new and stable prion state much
more frequently than wild-type Sup35 (7).
Oligopeptide repeats of various lengths and compositions
appear in several other amyloid-forming proteins in addition to
prion proteins. The huntingtin protein associated with Hun-
tington’s disease contains a perfect polyglutamine repeat, and
expansion of this repeat region results in early onset of the
disease and an increase in the rate of in vitro amyloid formation
(19, 20). -Synuclein, a protein that plays a role in Parkinson
disease and assembles into amyloid fibers in vitro, contains
seven copies of a less defined repeat, XKTKEGVXXXX (21).
The major and minor components of the Escherichia coli curli
protein each consist of five 16–18 mer repeats, which are
required for the formation of curli amyloid fibers and are
involved in cell aggregation, biofilm formation, and surface
adhesion (22, 23). Although oligopeptide repeats are clearly a
crucial feature of these amyloid-forming proteins, the exact
structural and functional role of these repeats remains unclear.
Compared with these other oligopeptide repeats, the bio-
physical properties of the PrP octarepeats are well character-
ized. The octarepeat of PrP can selectively bindCu(II) ions (24),
and the histidine residues in the octarepeats act as the primary
anchor point for Cu(II) binding (24). Structurally, Cu(II) bind-
ing can induce a conformational conversion of PrPC into pro-
tease-resistant species (10), and the efficiency of this conver-
sion depends on the number of octarepeats (17). Cu(II) ions
combined with nicotinamide adenine dinucleotide phosphate
(NADPH) can even induce spontaneous conformational
change and aggregation of HuPrP-(23–98), a variant that only
contains the octarepeat region of humanPrP (25). Functionally,
Cu(II) binding to the octarepeats induces PrPC endocytosis in
neuronal cells, indicating a role for PrPC in Cu(II) sensing,
uptake and/or transport (26). Superoxide dismutase (SOD)-like
activities have also been reported for the Cu(II)-bound PrPC,
suggesting a neuronal function of PrPC as an anti-oxidant (27–
29), although that is still a subject of debate (30). Treatment of
scrapie-infectedmice with Cu(II) chelator D-()-penicillamine
(D-PEN) delays the onset of prion disease in mice (31).
While the biophysical properties of the PrP repeats have been
studied extensively, the role of the repeats in prion conforma-
tional conversion is not well understood, particularly because
of the lack of knowledge on many details of PrP prion forma-
tion. One the other hand, the factors that guide prion confor-
mational conversion have been best defined for Sup35. These
factors includemolecular chaperones that influence conforma-
tional conversion (32–35), as well as specific sequence elements
that control the maintenance and nucleation of the prion con-
formation and govern the formation of distinct prions strains
and the existence of prion species barriers (36–40). To provide
a newmodel for studying prion conformational conversion and
to better understand the role of the oligopeptide repeats in
amyloid formation, we explored the role of the PrP octarepeats
in the context of the yeast prion protein Sup35. We created
chimeric proteins in which different numbers of hamster PrP
repeats were substituted for the endogenous Sup35 repeats.
Facilitated by the powerful genetic and biophysical techniques
developed for yeast prions, we were able to characterize how
the PrP octarepeats influence the conformational conversion
and amyloid formation of these chimeric prion proteins both in
vivo and in vitro.
We find that increasing the number of PrP repeats in the
chimeric proteins increases the spontaneous appearance of the
[PSI] phenotype in vivo and accelerates amyloid formation in
vitro. Conformational conversion and amyloid formation by
the chimeras are modulated by both pH and the presence of
metal ions. Further, the manner in which these factors modu-
late conversion is highly sensitive to the number of PrP repeats.
Our work offers new insight into the role of the PrP octarepeats
in amyloid formation and prion formation, with implications
for prion structure. It also allows us to control protein assembly
by simply altering environmental conditions. This control will
be useful for further functional and structural work and could
provide a practical means of controlling assembly for biomate-
rial and biotechnology applications.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Gene Integration—A Sup35 inte-
grative vector was constructed using pRS306 (41). A fragment
spanning from 1360 nucleotides upstream of Sup35 through
a 5-region of Sup35 with a BspE1 site after the first Sup35
repeat was amplified (PCR primers 5-CGACGGTATCGA-
TAAGCTTG-3 and 5-GATAGCCTCTAGATTGGTATC-
CGGAATAACCTTG-3) and ligated into pRS306 between
ClaI and XbaI sites. A second fragment spanning from Sup35
downstream from the repeats with an EagI site just after the
repeats to 800 nucleotides downstream from Sup35 was
amplified (PCR primers 5-CAGCAATCTAGACCACAAG-
GCGGCCGTGGAAATTAC-3 and 5-CGAATTGGAGC-
TCTTACTCG-3) and ligated into the plasmid between
XbaI and SacI sites. This plasmid was sequenced through the
entire Sup35 region, and was named pRS306Sup35R1.
The first two PrP repeats were added to pRS306Sup35R1
by annealing two complementary oligonucleotides and
inserting them between the BspE1 and EagI sites. To ensure
high purity of these lengthy oligos, they were ordered PAGE-
purified and phosphorylated from Research Genetics (oligo
sequences 5-CCGGATATCCACAAGGTGGAGGTACTT-
GGGGTCAACCCCATGGAGGTGGTTGGGGTCAACC-
ACAAGGC-3 and 5-GGCCGCCTTGTGGTTGACCCC-
AACCACCTCCGGGTTGACCCCAAGTACCTCCACCT-
TGTGGATAT-3), and contained a BstXI site. The resulting
plasmid was named pRS306Sup35R12. Subsequent repeats
were added by inserting annealed oligos encoding three PrP
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repeats in the BstXI site (oligo sequences 5-GAGGTTGG-
GGTCAACCCCATGGAGGAGGTTGGGGTCAACCCC-
ATGGAGGTGGTTGGGGTCAACCCCATGGAG-3 and
5-ATGGGGTTGACCCCAACCACCTCCATGGGGTTG-
ACCCCAACCTCCTCCATGGGGTTGACCCCAACCTC-
CTCC-3). The addition of one copy of these annealed oligos
created pRS306Sup35R15. The oligos contained two BstXI
sites, so digestion with BstXI and self-ligation created
pRS306Sup35R14, while digestion with BstXI and insertion of
another copy of the annealed oligos created pRS306Sup35R17.
In a similarmanner, pRS306Sup35R16 and pRS306Sup35R18
were created. All of these plasmids were sequenced through the
repeat region to confirm accuracy.
The plasmids for the R18H1Q chimera were created by the
same method, inserting oligos encoding PrP repeats in which the
histidines were changed to glutamines into pRS306Sup35R12
(oligo sequences 5-GAGGTTGGGGTCAACCC CAAGG-
AGGAGGTTGGGGTCAACCCCAAGGAGGTGGTTGG-
GGTCAACCCCAAGGAG-3 and 5-TTGGGGTTGACC-
CCAACCACCTCCTT GGGGTTGACCCCAACCTCCTC-
CTTGGGGTTGACCCCAACCTCCTCC-3). The plasmids
pRS306Sup35R18H1Q was created in this manner and
sequenced through the repeat region. Note that these plas-
mids still contained the one histidine that was present in the
repeats in pRS306Sup35R12.
Bacterial expression constructs for R14, R18, and
R18H1Q were created by excising the repeat region from
the corresponding integration constructs with BstEII and
MscI and ligating it into these sites in the expression con-
struct pJC25NMstop (42). These constructs were named
pJC25R14stop, pJC25R18stop and pJC25R18H1Q.
These plasmids were sequenced through the repeat region to
confirm accuracy.
Gene Integration and Replacement—The integration con-
structs were linearized withMluI and transformed into a [psi]
74-D694 (genotype: ade1–14(UGA), trp1–289(UAG), his3-
200, ura3-52, leu2-3,112) strain. Transformants were selected
on uracil-deficient medium (S.D.-Ura), and recombinant exci-
sion events were selected on medium containing 5-fluoro-
orotic acid. Strains in which the wild-type Sup35 gene had been
replaced by themutant copywere identified byPCRof a portion
of the genomic Sup35 gene. The repeat region of the Sup35
gene was sequenced to confirm accuracy.
Spontaneous Appearance of [PSI] in R1X Yeast Strains—
All R1X strains were grown on YPD plates, and then inocu-
lated in liquid YPD. After overnight growth, the cells were
plated onADE at 0.7 106, 1.4 106, and 6 106 cells/plate.
After 7 days of incubation, colonies were counted.
Protein Purification—Crude preparations of proteins were
purified as previously described (43). Mass spectrometry anal-
ysis yielded the followingmasses: R14 was 27171.1 Da (calcu-
lated value is 27170.1 Da), R18 was 30277.6 Da (calculated
value is 30277.3Da), and R18H1Qwas 30222.9 Da (calculated
value is 30223.3 Da). Protein concentrations were determined
using the absorbance at 280 nm with molar extinction coeffi-
cients calculated as 25,600 (NM), 39400 (R14), 62160 (R18),
and 62160 (R18H1Q).
Fiber Formation—Proteins were dissolved in 6 M guanidine
hydrochloride as a stock solution, and the concentration was
determined by the absorbance at 280 nm. Solutions for
unseeded polymerization reactions were prepared by dilution
of the stock solution into aqueous buffers and allowed to assem-
ble at room temperature either with our without agitation.
Seeds for seeded reactions were prepared by sonicating pre-
formed fibers in a VWR Aquasonic 50T water bath sonicator,
and all seeded reactions contained 2% (w/w) of the seeds.
The buffers for the tests at different pH values are: pH 7.2, 20
mM MOPS with 100 mM sodium chloride; pH 6.2, 5 mM potas-
siumphosphatewith 50mM sodium sulfate; pH4.9, 3.9, and 2.9,
5 mM potassium acetate with 50 mM sodium sulfate.
Cu(II) Binding Reactions—Lyophilized protein was first dis-
solved in acidified 25 mMNEM, 300 mMNaCl and spin filtered
through a 300 kDa cutoffmembrane. An appropriate volume of
100 mM CuCl2 in deionized water was added and samples were
mixed. Then samples were diluted to 5–20 M final protein
concentration using 30 mMNEM pH 8.1. All EPR samples con-
tained 20% (v/v) glycerol as a cryoprotectant.
Electron Spin Resonance Spectroscopy—X-band spectra (9.43
GHz) were acquired using a Bruker ELEXSYS E500 spectrom-
eter and a TE102 cavity. Measurements were performed at
115–125K in a nitrogen vapor using cavity equipped with
variable temperature control. The total boundCu(II) was quan-
tified by spin integration and comparison to accurate standard
solutions containing Cu(II) in 10 mM imidazole at pH 7.4.
Thioflavin-T Binding—Fiber formation was monitored by
Thioflavin-T (44) in both seeded and unseeded reactions (45).
Attenuated Thioflavin T (ThT) intensity was observed at acidic
pHs and in the presence of Cu(II), when SDS assay showed the
same amount of free monomers left after polymerization reac-
tions. ThT fluorescence intensity was baseline subtracted and
then normalized to the maximum intensity when the polymer-
ization reaction reached equilibrium.
Monitoring Fiber Formation by SDS Solubility—At the indi-
cated time points, 20l of the assemblymixwaswithdrawn and
added to SDS-PAGE sample buffer. Samples were run on 12.5%
SDS-PAGE gels and stained with Coomassie Blue G-250. The
percentage of soluble protein was calculated by (gel band inten-
sity at indicated time point) divided by (gel band intensity of
zero hour sample after boiling).
RESULTS
Chimeric Sup35 Proteins with PrP Repeats Can Support Both
the Prion andNon-prion States—We first constructed chimeric
proteins consisting of Sup35 with different numbers of PrP
repeats substituted for the repeats of Sup35. Because the first
repeats of Sup35 and PrP are the least similar to each other in
sequence, and since the first Sup35 repeat is spatially separated
from the others, we kept it intact. The last four full Sup35
repeats were replaced with the repeats from hamster PrP: one
copy of the first hamster PrP imperfect repeat (PQGGGT-
WGQ) followed by varying numbers of the perfect hamster PrP
repeats (PHGGGWGQ), as shown in Fig. 1A. Because our chi-
meras contained the first repeat (R1) of Sup35 plus two, four,
five, six, seven, and eight repeats, they were named R12,
R14, R15, R16, R17, and R18.
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We first asked how these chimeric proteins affected yeast
prion biology in vivo. Starting with [psi] cells, the wild-type
SUP35 gene was replaced with a gene encoding R12, R14,
R15, R16, R17, or R18 by homologous recombination.
The strain we employed contains a nonsense codon in the
ADE1 gene. In [PSI] cells, wherein most of the Sup35 transla-
tion termination factor is sequestered in prion aggregates, ribo-
somes sometimes read through the stop codon. This allows the
cells to grow on adenine deficient media (S.D.-Ade) and causes
them to form white colonies when grown on rich media (YPD)
(46, 47). The [psi] cells do not grow on S.D.-Ade, and produce
red colonies on YPD because of the accumulation of a meta-
bolic by-product of adenine biosynthesis (46). Strains in which
wild-type Sup35 was replaced with R12 through R18 sub-
stitutions remained [psi].
Increasing the Number of PrP Repeats Destabilizes Both the
[psi] and [PSI] States—When wild-type cells are grown in
YPD, they are stable in both the [PSI] and the [psi] states, and
the rate of spontaneous conversion between these states is very
low (7). To determine the stability of the [psi] state in our
mutant strains, we observed the spontaneous appearance of
[PSI] by streaking [psi] cells on YPD followed by an S.D.-Ade
plate. Wild-type Sup35 [psi] strains produced colonies on
S.D.-Ademedium rarely, approximately one per 106 cells/plate.
R12, R14, R15, also rarely produced colonies. In contrast,
colonies appeared 10-fold more frequently on S.D.-Ade
mediumwith R16 and100-foldmore frequently with R17
and R18 strains. The colonies were confirmed as being true
[PSI] colonies by taking advantage of the fact that cells can be
cured of the prion state by growing them on media containing
guanidine hydrochloride. This pro-
duced red colonies that could not
grow on S.D.-Ade medium. Thus,
repeat expansion increased rate of
spontaneous conversion from the
[psi] to the [PSI] state.
Next we examined the spontane-
ous conversion of R1X [PSI]
strains to [psi]. To create [PSI]
strains of R12, R14, R15, and
R16, large numbers of the [psi]
strains were plated on S.D.-Ade and
colonies that grewwere selected. All
of the [PSI] strainswere confirmed
by growth and curing in the pres-
ence of 5 mM GdnHCl. Fig. 1B
shows the growth of R1X strains
in both [psi] and [PSI] states on
YPD. When R12, R14, R15,
and R16 [PSI] strains were
grown on YPD-rich medium, the
colonies appeared white, and red
colonies were rarely observed, simi-
lar to wild-type Sup35 [PSI]
strains. Thus, the [PSI] states of
R12, R14, R15, and R16
were maintained stably. However,
R17 and R18 strains frequently
converted to [psi] on YPD plates, with the colonies sectoring
to red around the perimeter. Thus, extra copies of the PrP oct-
arepeats destabilize both the prion and non-prion states.
Increasing the Number of PrP Repeats Dramatically Acceler-
ates Amyloid Formation in Vitro—Sup35 can be divided into
three distinct regions, the N terminus with the oligopeptide
repeats (amino acids 1–123), a highly charged middle region,
and the C terminus (amino acids 254–685), which functions as
a translation termination factor. The N terminus (N) and the
middle region (M) of Sup35, often called NM, forms the prion-
determining (PrD) domain. In vitro assembly of NM amyloid
fibers recapitulates the induction and propagation of yeast pri-
ons in vivo (7, 39, 48, 49), and transformation of NM fibers into
[psi] yeast cells (50) induces the formation of yeast prion phe-
notypes (36, 39, 48). To examine the amyloidogenic properties
of the R1X proteins, we chose to purify the NM domains of
wild-type Sup35, R14, and R18. Amyloid fibers formed by
the R14 and R18 chimeras were examined by atomic
force microscopy (AFM). They were morphologically indis-
tinguishable from those formed by wild-type NM (supple-
mental Fig. S1).
The kinetics of amyloid formation were monitored both by a
Thioflavin-T (ThT) binding assay and by an assay for resistance
to solubilization by SDS (46). Wild-type NM or chimeric NMs
were diluted from a 6 M GdnHCl stock solution into aqueous
buffer and incubated at room temperature with agitation, a
standard condition that accelerates assembly. Under these con-
ditions, all of the proteins exhibited behavior typical of sponta-
neous, nucleated amyloid formation, with an initial lag phase
followed by an assembly phase (Fig. 2A). However, wild-type
FIGURE 1. A, replacement of the Sup35 repeats with repeats from PrP. The last four repeats of wild-type Sup35,
spanning residues 56–93, were replaced by the first repeat from hamster PrP and then various numbers of
copies of the second repeat from hamster PrP. Chimeric proteins therefore contained the first Sup35 repeat
plus 2, 4, 5, 6, 7, and 8 PrP repeats, and sowere named R12, R14, R15, R16, R17, and R18. The amino
acids fromtheSup35 sequenceare in red, and those fromPrPare inblack.B, all of theR1Xchimeras supported
both [PSI] and [psi] states. The strains were spotted on YPD.
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NM and the chimeras exhibited very different lag times. Both
chimeras with PrP repeats showed a shorter lag phase than
wild-type NM. Moreover, R18 exhibited a shorter lag phase
than R14. These experiments were performed many times
with independent protein preparations. Although the absolute
lag times varied somewhat from experiment to experiment,
the differences between the behavior of three proteins were
extremely consistent. This result indicates that the PrP octare-
peat is more amyloidogenic than the Sup35 repeat, and that the
number of PrP octarepeats can greatly alter the intrinsic capac-
ity of the proteins to form amyloid.
To test the effects of the PrP repeats on the assembly phase of
amyloid formation, seeded polymerization reactions were
monitored. Pre-formed NM fibers seeded fiber formation of
wild-type NM with elimination of the lag phase (46) (Fig. 2B).
Wild-type NM fibers also effectively seeded fiber formation of
R14 and R18 (2% w/w seed, Fig. 2B). Moreover, all three
proteins were able to effectively cross seed each other (Fig. 2B).
In all seeded reactions and regardless of the nature of the seeds
R18 assembled much faster than R14 and wild-type NM.
These findings were confirmed by SDS resistance assay (data
not shown). Thus, the number of the PrP repeats influences
both the spontaneous nucleation rate and the inherent assem-
bly rate of amyloid formation. But strikingly, the repeats have
little effect on seeding or cross-seeding capacity.
Histidine Residues in the PrPRepeats Confer pHSensitivity on
Amyloid Formation—We then explored the factors that may
affect the conformation of the repeat region and thereby the
process of amyloid formation. Previous studies showed that
conformational conversion of truncated PrPs free of the repeat
region was sensitive to pH (51–53) and the remaining histidine
residues in the truncated PrP were suggested to be crucial for
this pH sensitivity (54). To our knowledge, the role of histidines
in the octapepetide repeats has not
been well tested. To examine the
effect of pH on the spontaneous
assembly of the chimeras, we used
quiescent reaction conditions,
which extend the lag phase. Amy-
loid formation by wild-type NM,
R14 and R18 in buffers with dif-
ferent pH values was monitored by
both ThT (Fig. 3A) and SDS (sup-
plemental Fig. S2) assays. The lag
phase of wild-type NM was insensi-
tive to pH, with similar amyloid for-
mation time courses at pH 7.2, 6.2,
4.9, 3.9, and 2.9. In contrast, lower-
ing the pH lengthened the lag phase
for both R14 and R18, with the
effect especially profound for R18.
The lag phase for R18 was less
than 2 h at pH 7.2 and 6.2, but it was
more than 10 h at pH 4.9 and more
than 30 h at pH 2.9. We also inves-
tigated the effects of pH on seeded
assembly (Fig. 3B and supplemental
Fig. S3). The assembly rate of wild-
type NM remained almost unchanged. However, the assembly
rate of R14 and R18 decreased at lower pH. Moreover,
R18 was more sensitive to pH changes than R14, particu-
larly at pH 4.5.
To directly test whether the histidine residues are responsi-
ble for the pH dependence of assembly, we mutated the histi-
dines in the repeat region of R18 to glutamines (changing
PHGGGWGQ to PQGGGWGQ). Glutamine was chosen since
it is present in the first imperfect repeat (PQGGGTWGQ) in
the same location as the histidine in the subsequent PHGGG-
WGQ repeats (Fig. 1A). Because of details of the cloning pro-
cedure, the histidine was not removed from the second PrP
repeat. Therefore, this new chimera contained only a single PrP
repeat with histidine, and was named R18H1Q. The histidine
replacement had no obvious effect on the function of the pro-
tein in vivo: R18H1Q strains supported both [PSI] and
[psi] states, and the purified NM domain of R18H1Q
formed amyloid fibers in vitro (supplemental Fig. S1). However,
unlike the R14 and R18 proteins with histidines in the
repeats, both the spontaneous nucleation rate and the assembly
rate for amyloid formation by R18H1Q was almost
unchanged across the entire tested pH range, frompH7.2 to 2.9
(Fig. 3, A and B). Thus, the histidine residues are the primary
source of the pH sensitivity of amyloid formation by the R14
and R18 proteins.
Interplay between Cu(II) and PrP Repeats Shows Complex
Effects on Amyloid Formation in Vitro—It has been extensively
shown that the PrP repeats can selectively bind Cu(II) ions (24,
55–58). Therefore, we explored the effect of Cu(II) on the con-
formational conversion and amyloid formation of the chimeras.
First, we investigated theCu(II)-binding sites in non-assembled
NM and R1X proteins by Electron Paramagnetic Resonance
(EPR). EPR has been previously applied to determine the
FIGURE 2.Proteins formamyloid fiberswith a lagphase that is eliminatedby the addition of pre-formed
fiber seeds, as monitored by ThT binding. A, in unseeded reactions, proteins with more repeats form amy-
loid fibers with a shorter lag phase. B, lag phase for fiber formation is eliminated for all proteins by the addition
of 2% (w/w) pre-formed fibers from any of the other proteins. All reactions use 5 M solutions of soluble
proteins of the NM domains of wild-type Sup35 (open circles), R14 (filled circles), and R18 (open squares).
Polymerization reactions were performed at room temperature under gentle rotation conditions. ThT fluores-
cence intensity was normalized to themaximum intensity when the polymerization reaction reached an equi-
librium determined by both the ThT and SDS-PAGE assays.
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molecular features of the Cu(II)-binding sites in recombinant
full-length Syrian hamster PrPC (59). Those results showed that
Cu(II) coordination depends highly on the relative concentra-
tion of Cu(II) to PrPC (60). With excess amount of Cu(II), cop-
per fully occupies individual repeat units, one Cu(II) per repeat
unit, coordinating with the His imidazole and two deproto-
nated glycine amides (59, 61). The EPR spectra of Cu(II)-bound
R14 and R18 are nearly indistinguishable from that of
Cu(II)-bound recombinant PrPC at full occupancy (60),
although in R18 there may be additional broadening in the
parallel region (2700 G–3100 G; Fig. 4). This broadening is
possibly due to Cu(II)-Cu(II) dipolar interactions. On average,
R14 bound 4–5 equivalents of Cu(II), and R18 bound up to
10 equivalents. Wild-type NM and R18H1Q bind Cu(II) at
2 and 4 equivalents, respectively. They might bind Cu(II) via
histidine residues outside the octarepeat region, and/or the free
amino group at the N terminus. R18H1Q retains a single his-
tidine-containing repeat, which is also likely responsible for the
additional Cu(II) binding compared with wild-type NM.
We then investigated the effects of Cu(II) on amyloid for-
mation by the R1X chimeras. 10 equivalents of Cu(II) were
added into NM and R14 solution, and 20 equivalents were
added into R18 and R18H1Q. As a result, the ratio of
[Cu(II)]/[single repeat] is constant, eliminating a variable
that influences Cu(II) coordination environment (60). For-
mation of amyloid fibers of all R1X proteins and NM in the
presence of Cu(II) was confirmed by AFM, morphologically
similar to that formed in the absence of Cu(II) (supplemental
Fig. S4). By the ThT assay, Cu(II) had no obvious effect on
the assembly of wild-type NM, but it did affect the lag phase
of fiber formation by the chimeric NMs (Fig. 5). For R14,
the presence of 10 equivalents of Cu(II) slightly accelerated
assembly. In contrast, Cu(II) showed an opposite effect on
R18, reducing assembly by increasing the lag phase by
FIGURE 3. A, lag times of amyloid formation for the R1X proteins and wild-type NM showed different sensitivities to pH, as monitored by the ThT binding
assay. The graphs show fiber formation in 5 M solutions of the NM domains of wild-type Sup35, R14, R18, and R18H1Q at room temperature without
rotation. The reactions were carried out at pH 2.9 (filled triangle), 3.9 (open circles), 4.9 (filled circles), 6.2 (open squares), and 7.2 (filled squares). B, propagation of
amyloid fibers of the R1X proteins is affected by pH, as monitored by SDS assay. The graphs show the assay for fiber formation in 2.5M solutions of the NM
domains of wild-type Sup35, R14, R18, and R18H1Q with 2% (w/w) of seed from the same protein type. The reactions were carried out at pH 2.7 (open
circles), 4.5 (filled circles), 6.4 (open squares), and 7.7 (closed squares).
FIGURE 4.EPR spectra of recombinant PrPC, R14, andR18 fully loaded
with Cu(II). R14 and R18 reveal binding components 1 and 2 (parallel
hyperfine features labeled) indistinguishable from those observed for recom-
binant PrPC. The recorded spectra are from monomeric protein in complex
with Cu(II), because centrifugation to remove aggregates (after spin) did not
alter the spectral features. Samples were prepared in 27.5 mM NEM, 150 mM
NaCl, pH 7.7.
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about a factor of 2. (This surprising difference in the effects
of Cu(II) was confirmed on independent protein prepara-
tions by two investigators, V.G. and J.D.) Cu(II) showed no
effect on the lag phase of R18H1Q fiber formation. Thus,
Cu(II) must modulate the lag phase of R18 amyloid assem-
bly by interacting with the histidine residues of the PrP
repeats. Results obtained with Thioflavin T fluorescence
were confirmed by the SDS-resistance assay (supplemental
Fig. S5).
Recombinant PrPC binds to Cu(II), Zn(II), andNi(II), but has
no detectable interaction with other metals, such asMn(II) (55,
57, 58). To test the specificity of Cu(II) on the R1X proteins,
we examined the effects of Zn(II) and Mn(II) on amyloid for-
mation of R14 and R18. Both ThT binding (Fig. 5) and SDS
assay (supplemental Fig. S5) showed that, as expected from the
binding selectivity, Mn(II) did not affect the lag phase of fiber
formation for either protein. Zn(II), however, modulated fiber
formation of R14, R18, and R18H1Qwith the same trend
as Cu(II), increasing the lag phase of R18 amyloid formation,
decreasing the lag phase of fiber formation of R14, and having
no effect on R18H1Q. Thus, the effects of metal ions on the
polymerization of the R1X proteins reflect how the ions rank
in their selectivity of binding to recombinant PrPC (55, 57, 58).
DISCUSSION
To provide a model system for studying oligopeptide repeats
in amyloidogenic proteins, we replaced the oligopeptide
repeats of Sup35 with the well-characterized octarepeats of
PrP. The resulting chimeric proteins allowed us to characterize
the properties of the PrP repeats in the context of both yeast
prion formation and amyloid assembly. The chimeric proteins
are fully capable of supporting the induction and maintenance
of the yeast [PSI] phenotype. R14, the chimera with the
same number of repeats as wild-type NM, forms amyloid fibers
more rapidly than NM, establishing that the PrP octapeptide
repeats aremore amyloidogenic than Sup35 repeats. Expanding
the number of PrP repeats greatly increases the rate of amyloid
assembly in vitro and the spontaneous appearance of [PSI] in
vivo. We previously showed that expanding the number of
endogenous Sup35 repeats accelerates amyloid formation and
increases the spontaneous rate of [PSI] appearance (7). Thus,
the two types of repeats have a very similar effect on amyloid
conformational conversion and on yeast prion biology.
Curiously, expanding the number of repeats destabilized the
[PSI] and [psi] states, increasing switching in both direc-
tions. Both results can be explained by our finding that R18 is
more amyloidogenic than R14. In destabilizing the [psi]
state, it seemsmost likely that R18 simply converts spontane-
ously into the amyloid prion state, [PSI], more frequently than
does R14. But how might a greater propensity to form an
amyloid destabilize the [PSI] state? There are at least two
likely possibilities based on our current findings. First, R18
amyloidsmay be too stable to be severed byHsp104 for efficient
transmission to daughter cells. A reduced partitioning rate
would lead to the loss of [PSI] (62). Second, the increased
efficiency of amyloid conversion might sequester too much of
the Sup35 essential translation-termination activity. This
would provide a selective advantage to cells that switch to the
[psi] state. A third, alternative explanation is that the repeats
interact with Hsp104 leading to increased disassembly of the
prion (18).
In any case, the strong effects of repeat expansions are
intriguing. We previously proposed that [PSI] provides a
mechanism for cells to switch heritably between distinct phe-
notypic states (63, 64). It may be that the number of repeats in
Sup35, and the degree of their amyloidogenicity, has been sub-
ject to evolutionary pressures to optimize switching rates
according to the frequency of environmental change.
The model substrates we have created allow multiple meth-
ods for interrogating the ways in which repeats can influence
amyloid formation. As shown for wild-type NM, a collapsed
oligomeric intermediate facilitates the intermolecular contacts
required for nucleation (32, 36, 40, 65). In our chimeras, the
structures populated by the collapsed intermediate can be
modulated by the number of repeats, by pH and by metal ions,
and each of these factors dramatically influences the lag time of
unseeded polymerization. Thus, these substrates, together with
new methods of single molecule fluorescence (66), should pro-
vide powerful new tools to study the biophysics of conforma-
tional conversion, both in nucleation and polymerization.
Indeed, results from the initial analysis reported here already
have interesting implications. First, although wild-type NM
and R14 have very different spontaneous nucleation rates
they have virtually identical seeded polymerization rates. The
increased amyloidogenicity of R14 compared with NM, then,
is solely due to a change in spontaneous nucleation. Second,
FIGURE 5.Different divalentmetal ions [Cu(II), Zn(II), andMn(II)] showed
different effects on the lag phase of amyloid formation by thewild-type
NM, R14, R18, and R18H1Q, as monitored by ThT binding. Metal
ionswere added in 10 equivalents for NMand R14 and in 20 equivalents for
all other proteins. Polymerization reactionswere performed at room temper-
ature with a gentle shaking at 600 rpm. Metal ion-free samples (open circle),
samples containing Cu(II) (solid circle), Zn(II) (open square), and Mn(II) (solid
triangle).
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R14 and NM have much slower rates of seeded polymeriza-
tion than R18. Third, andmost strikingly, these very different
rates of seeded polymerization are independent of the seed.
That is, seeds formed by R18, by R14, or by wild-type NM
cross-seed polymerization of all three proteins in the very same
way. These results fit well with one structural model for NM
fibers, but not another. In themodel proposed by Shewmaker et
al. (67), the residues of the N domain stack upon each other,
with the repeat region forming an extensive intermolecular
interface. Under this model, it would be hard to understand
why replacing 38 amino acids (out of 123) in theN domain with
64 heterologous amino acids from the PrP protein, has virtually
no effect on cross seeding activity. In the second model by
Krishnan et al. (36), the repeat region is largely sequestered
from intermolecular contacts. The repeats are envisioned as
coiling upon each other during amyloid formation, which
would be consistent with facilitated nucleation we observe with
expanding the repeats. However, intermolecular contacts are
primarily made by flanking regions in this model (36). Efficient
cross-seeding between wild-type NM and the two chimeras
would therefore be expected, since they contain the same
sequences in the flanking regions for inter-molecular contacts
(36, 40, 65).
Further study of these chimeric proteins might also help us
understand the effects of the PrP repeats, pH andmetal ions, on
prion initiation by wild-type PrP. Although the repeats are out-
side the main amyloid core of PrP and lie within it in NM, their
collapse into a compact, molten folding intermediate might
affect PrP andNMnucleation in a similar way, by freeing flank-
ing regions to make their critical nucleating contacts. Acidic
conditions facilitate the conversion of the C-terminal segment
of PrPC into aggregation-prone conformations (51–53), while
the pH dependence of full-length PrP is not well established.
Our chimeric proteins show decreased assembly rates under
acidic conditions, and this effect is profound for proteins with
repeat expansions. Such pH sensitivities may be of importance
in disease since one compartment that might be involved in the
conversion of PrPC to PrPSc is the acidic endosome (68, 69). The
PrP repeats also interact with metal ions, especially Cu(II),
which also has suggested roles in prion diseases (70, 71).
Although our work does not directly address how such Cu(II)-
repeat interactions affect conformational conversion in full-
length PrP, it does provide strong evidence that Cu(II) (and
Zn(II)) can induce a major conformational rearrangement in
the repeats that can affect subsequent amyloid formation. The
differential effect of Cu(II) ions on R14 versus R18 may be
due to different binding environments of Cu(II) upon assembly
(24, 56, 59–61, 72), although non-assembled R14 and R18
have similar coordination environments indicated by the EPR
studies. On the other hand, EPR spectrum broadening was
observed for the soluble R18 protein, suggesting a dipolar-
dipolar interaction, which may result in a very different
arrangement of the individual repeat units in R18 versus in
R14. Potentially different arrangements of the repeat units
could result in different collapse rates and/or stabilities of the
oligomeric intermediates. Interestingly, Cu(II) stimulates
endocytosis of wild-type PrPC in human neuroblastoma cells,
whereas such an event is compromised with expanding the
number of the repeats (26). Either deletion or expansion of the
repeat region also interferes with Cu(II)-induced association of
the PrP repeat region that is fused to a GST protein (17). Thus,
more or less than the optimal number of four consecutive
repeats results in profound changes in PrP structure and func-
tion, and this may be one influence on the high conservation of
repeat number during evolution.
Efforts to understand and control the assembly of amyloido-
genic proteins are inspired not only by their importance in
diverse biological processes, but also their potential applica-
tions in nanotechnology (73, 74). NM fibers are stable under a
wide variety of conditions and can incorporate a diversity of
functions, including the binding of metals that allow them to
form nanowires and electronic circuits (74). The NM chimeras
with PrP repeats offer new methods for controlling assembly
with pH and metal ions, and further raise the possibility of
adapting such architectures for novel materials and biotechno-
logical applications. For example, when the chimeras and wild-
type NM are mixed together for assembly under different pH,
different ratios of the chimeras and NM will be incorporated
into individual fibers. If a single cysteine mutation is presented
in the chimeras, but not in wild-type NM, different chemical
moieties can be introduced via the cysteine on the chimeras but
not on wild-type NM. As a result, controlled and fine-tuned
patterning and mixing of chemical moieties covalently bound
to the mixed fibers can be achieved. This will significantly
broaden functional diversity and specificity of these self-assem-
bly-based nanomaterials. In sum, modification of NM by sub-
stituting the endogenous repeatswith those of PrP has provided
insights on assembly that offer additional promise for the
future.
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